These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

916 related articles for article (PubMed ID: 22592049)

  • 1. Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.
    Lee LJ; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1192-7. PubMed ID: 22592049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept.
    Fokdal L; Tanderup K; Nielsen SK; Christensen HK; Røhl L; Pedersen EM; Schønemann NK; Lindegaard JC
    Radiother Oncol; 2011 Sep; 100(3):473-9. PubMed ID: 21924784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaginal Dose Is Associated With Toxicity in Image Guided Tandem Ring or Ovoid-Based Brachytherapy.
    Susko M; Craciunescu O; Meltsner S; Yang Y; Steffey B; Cai J; Chino J
    Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1099-105. PubMed ID: 26883564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of high-dose-rate interstitial gynecologic brachytherapy using real-time CT guidance.
    Lee LJ; Damato AL; Viswanathan AN
    Brachytherapy; 2013; 12(4):303-10. PubMed ID: 23491023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of severe gastrointestinal toxicity after external beam radiotherapy and interstitial brachytherapy for advanced or recurrent gynecologic malignancies.
    Kasibhatla M; Clough RW; Montana GS; Oleson JR; Light K; Steffey BA; Jones EL
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):398-403. PubMed ID: 16542793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results.
    Dimopoulos JC; Schmid MP; Fidarova E; Berger D; Kirisits C; Pötter R
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1880-8. PubMed ID: 21868174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer.
    Wang CJ; Huang EY; Sun LM; Chen HC; Fang FM; Hsu HC; Changchien CC; Leung SW
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):179-89. PubMed ID: 15093915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance-guided interstitial therapy for vaginal recurrence of endometrial cancer.
    Viswanathan AN; Cormack R; Holloway CL; Tanaka C; O'Farrell D; Devlin PM; Tempany C
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):91-9. PubMed ID: 16839709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computed tomography-planned interstitial brachytherapy for locally advanced gynecologic cancer: Outcomes and dosimetric predictors of urinary toxicity.
    Amsbaugh MJ; Bhatt N; Hunter T; Gaskins J; Parker L; Metzinger D; Amsbaugh A; Sowards K; El-Ghamry MN
    Brachytherapy; 2016; 15(1):49-56. PubMed ID: 26614237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaginal tolerance of CT based image-guided high-dose rate interstitial brachytherapy for gynecological malignancies.
    Murakami N; Kasamatsu T; Sumi M; Yoshimura R; Harada K; Kitaguchi M; Sekii S; Takahashi K; Yoshio K; Inaba K; Morota M; Ito Y; Itami J
    Radiat Oncol; 2014 Jan; 9():31. PubMed ID: 24456669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients.
    Ribeiro I; Janssen H; De Brabandere M; Nulens A; De Bal D; Vergote I; Van Limbergen E
    Radiother Oncol; 2016 Sep; 120(3):447-454. PubMed ID: 27157510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late rectal toxicity after image-based high-dose-rate interstitial brachytherapy for postoperative recurrent and/or residual cervical cancers: EQD2 predictors for Grade ≥II toxicity.
    Chopra S; Dora T; Engineer R; Mechanery S; Agarwal P; Kannan S; Ghadi Y; Swamidas J; Mahantshetty U; Shrivastava SK
    Brachytherapy; 2015; 14(6):881-8. PubMed ID: 26409708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bladder distension on doses to organs at risk in Pulsed-Dose-Rate 3D image-guided adaptive brachytherapy for locally advanced cervical cancer.
    Nesseler JP; Charra-Brunaud C; Salleron J; Py JF; Huertas A; Meknaci E; Courrech F; Peiffert D; Renard-Oldrini S
    Brachytherapy; 2017; 16(5):976-980. PubMed ID: 28694116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computed tomography planned interstitial brachytherapy for recurrent gynecologic cancer.
    Amsbaugh MJ; Bhatt N; Hunter T; Gaskins J; Parker L; Metzinger D; Amsbaugh A; Sowards K; El-Ghamry M
    Brachytherapy; 2015; 14(5):600-5. PubMed ID: 26087868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Point vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data.
    Yaparpalvi R; Mutyala S; Gorla GR; Butler J; Mah D; Garg MK; Kalnicki S
    Brachytherapy; 2008; 7(4):336-42. PubMed ID: 18782683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose-rate interstitial brachytherapy for gynecologic malignancies.
    Beriwal S; Bhatnagar A; Heron DE; Selvaraj R; Mogus R; Kim H; Gerszten K; Kelley J; Edwards RP
    Brachytherapy; 2006; 5(4):218-22. PubMed ID: 17118313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
    Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
    Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.